Opzelura (ruxolitinib) cream 1.5%

Opzelura cream is a topically applied JAK inhibitor indicated for the treatment of atopic dermatitis in patients 2 years and older and for nonsegmental vitiligo in patients 12 years and older. The package insert contains the same boxed warnings that have been applied to oral JAK inhibitors and include warnings about malignancy, major adverse cardiovascular events, thrombosis, serious infections, and death; but there is no evidence that these are increased with topical application of Opzelura cream.  The package insert recommends against using in combination with biologics, other JAK inhibitors, or immunosuppressive drugs such as azathioprine and cyclosporine; but in clinical practice, Opzelura cream is often used in combination with other treatments for atopic dermatitis such as biologic therapies.